Dubai
Master Diagnóstica (Granada, Spain), signed an exclusive distribution agreement with the Alliance Global Group (Dubai, UAE) to bring their innovative DNA Flow Technology to the MEA region.
“We believe that DNA Flow Technology of Master Diagnóstica coupled with the important assays available for Sepsis, Meningitis and HPV will enable our customers to reach precise diagnosis for these critical infections in a much shorter time, and we expect a lot of our customers to be extremely interested in what Master Diagnóstica has to offer”, says Nicolò Conti, Product Manager – Molecular Diagnostics at Alliance Global.
“We are very excited to work with AGBL and to utilize their extensive sales and support network in the region, our technologies today serve customers in more than 50 markets and we consider the partnership with AGBL to be strategic to double the number of countries where patients can benefit from our technology”, says David Chaves Assislau, International Sales Manager at Master Diagnóstica.
-Ends-
About Master Diagnostica
Master Diagnóstica is a Spanish biotechnology company incorporated in 1996 devoted to the development, manufacturing and sales of diagnostic kits and reagents for in vitro diagnosis. It addresses oncological, infectious and other type of diseases by using innovative molecular biology and immunohistochemistry technologies. They are one of the main Spanish providers in the Pathology field and related services.
About Alliance Global Group:
The AGBL Group of companies is the largest biomedical gateway to the emerging markets of the Middle East, Africa and Asia. The group is dedicated to bringing innovative technologies and products to researchers, clinicians, and diagnostic users in the emerging healthcare markets within the MEAA region. The group employs more than 100 specialists and has ten regional offices offering distribution, consulting and product development services to more than 40 quality manufacturers of biomedical technologies. The group’s stated mission is “to improve the lives of the region’s inhabitants through novel biomedical technologies and products.”
For more information, please visit: www.agbl.net
© Press Release 2016
